The study of TCMCB07 for the treatment of cancer cachexia
Endevica Bio is starting a new clinical trial of A Study to Assess the Safety, Tolerability and Pharmacokinetics of TCMCB07 in Single and Multiple Ascending Doses in Health Subjects.
This study will test an experimental drug named TCMCB07 for the treatment of cancer cachexia. Cachexia is a syndrome characterized by weight loss, anorexia, weakness or lack of energy, and anemia. Cachexia occurs in many cancers, usually at the advanced stages of disease.
The clinical trial started in July 12, 2022 and will continue throughout January 2023.
Number of people with an Adverse Event Assessment will be primary outcome measure. Adverse Event monitoring.
The inclusion parameter is: healthy males and females (WONCBP), aged 18 to 55 years inclusive, at time of signing informed consent; body mass index 18.0 to 30.0 kg/m2 as measured at Screening or, if outside this range, considered not clinically significant by the investigator; weight ≥ 50 kg at Screening.
For more details and the complete list of the inclusion and exclusion criteria visit: https://ichgcp.net/clinical-trials-registry/NCT05529849.
The location is Quotient Sciences, Inc, Miami, Florida, United States.
